Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dapoxetine→

Dapoxetine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
119356-77-3
Molecular formula
C21H23NO
Molecular weight
305.4 g/mol
Drug class
Short-acting selective serotonin-reuptake inhibitor (SSRI)
Mechanism of action
Inhibits neuronal serotonin reuptake and increases serotonergic activity at pre- and postsynaptic receptors. Its effect on premature ejaculation is presumed to involve modulation of serotonergic control of the ejaculatory reflex.
Indications / reported uses
  • On-demand treatment of premature ejaculation in adult men who meet the applicable product-specific diagnostic and eligibility criteria; the cited EU/UK product indication covers men aged 18–64 years

Sources: NICE evidence summary — Dapoxetine for premature ejaculation · EMA referral — Priligy · European Association of Urology guideline

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dapoxetine Environmental Risk Assessment (ERA) (the Dapoxetine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.